Vir Biotechnology, Inc.
Vir Biotechnology, Inc.（VIR）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · VIR · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
57
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Vir Biotechnology, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
VIR 季度内部人买卖趋势
VIR 内幕交易卖出 · VIR 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · VIR CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
VIR 高管卖出股份 · VIR 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 1, 2026 | Napolitano Janet Director | Sale | 3,200 | $30K | Form 4 |
| May 27, 2026 | Sigal Charles Elliott Director | Award | 8,000 | — | Form 4 |
| May 27, 2026 | Napolitano Janet Director | Award | 8,000 | — | Form 4 |
| May 27, 2026 | MORE ROBERT J Director | Award | 8,000 | — | Form 4 |
| May 27, 2026 | Hatfield Jeffrey S. Director | Award | 8,000 | — | Form 4 |
| May 27, 2026 | Farid Ramy Director | Award | 8,000 | — | Form 4 |
| May 27, 2026 | BISCHOFBERGER NORBERT W Director | Award | 8,000 | — | Form 4 |
| May 1, 2026 | SATO VICKI L Director | Sale | 22,000 | $221K | Form 4 |
| Apr 29, 2026 | De Backer Marianne President and CEO · Director | Other | 233,532 | — | Form 4 |
| Apr 29, 2026 | De Backer Marianne President and CEO · Director | Other | 233,532 | — | Form 4 |
| Apr 6, 2026 | De Backer Marianne President and CEO · Director | Sale | 72,559 | $664K | Form 4 |
| Apr 1, 2026 | SATO VICKI L Director | Sale | 22,000 | $200K | Form 4 |
| Mar 2, 2026 | SATO VICKI L Director | Sale | 21,800 | $207K | Form 4 |
| Mar 2, 2026 | SATO VICKI L Director | Sale | 200 | $2K | Form 4 |
| Feb 24, 2026 | SATO VICKI L Director | Option | 42,377 | $63K | Form 4 |
| Feb 24, 2026 | SATO VICKI L Director | Sale | 42,177 | $411K | Form 4 |
| Feb 24, 2026 | SATO VICKI L Director | Sale | 200 | $2K | Form 4 |
| Feb 24, 2026 | Eisner Mark EVP and Chief Medical Officer | Sale | 1,616 | $15K | Form 4 |
| Feb 25, 2026 | Eisner Mark EVP and Chief Medical Officer | Sale | 1,889 | $19K | Form 4 |
| Feb 24, 2026 | De Backer Marianne CEO · Director | Sale | 14,762 | $141K | Form 4 |
| Feb 22, 2026 | Eisner Mark EVP and Chief Medical Officer | Award | 55,000 | — | Form 4 |
| Feb 23, 2026 | Eisner Mark EVP and Chief Medical Officer | Sale | 2,089 | $16K | Form 4 |
| Feb 22, 2026 | De Backer Marianne CEO · Director | Award | 285,000 | — | Form 4 |
| Feb 23, 2026 | De Backer Marianne CEO · Director | Sale | 19,039 | $142K | Form 4 |
| Feb 2, 2026 | SATO VICKI L Director | Sale | 22,000 | $170K | Form 4 |
De Backer Marianne
President and CEO · Director
日期
Apr 6
股数
72,559
均价
$9.16
总金额
$664K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 VIR 内幕交易
VIR 内幕交易
Vir Biotechnology, Inc.（VIR）内幕交易数据来源于公司内部人（包括SVF Endurance (Cayman) Ltd (10 percent owner), SATO VICKI L (Director), De Backer Marianne (President and CEO · Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。VIR内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Vir Biotechnology, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
VIR 内幕交易 · 5个问题Vir Biotechnology, Inc.（VIR）的内部人包括高管和董事，如SVF Endurance (Cayman) Ltd (10 percent owner), SATO VICKI L (Director), De Backer Marianne (President and CEO · Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026